Shares of Acadia Pharmaceuticals have surged to a fresh annual peak, establishing a powerful upward trajectory. The stock achieved a new high for the year on August 25, reaching $25.90 (€21.82). This milestone caps a remarkable rally, with the equity climbing more than 42% since the middle of May 2025.
Robust Quarterly Performance Fuels Momentum
The company’s impressive second-quarter 2025 earnings report served as a significant catalyst for this recent acceleration. Acadia posted earnings per share (EPS) of $0.16, outperforming analyst projections of $0.14. Revenue for the quarter also exceeded expectations, coming in at $264.6 million against a consensus forecast of $262.44 million.
This financial strength was primarily driven by the performance of its key products:
* Nuplazid generated sales of $168.5 million, meeting market expectations.
* Daybue was a standout, surpassing all forecasts with robust revenue of $96.1 million.
Should investors sell immediately? Or is it worth buying Acadia?
Management Boosts Full-Year Guidance
Reflecting confidence in its ongoing commercial execution, Acadia’s leadership revised its full-year 2025 financial outlook upwards. The updated guidance now anticipates:
* Total revenue between $1.045 billion and $1.095 billion, raised from the previous range of $1.030 billion to $1.095 billion.
* Nuplazid revenue is now projected to be $665 million to $690 million, increased from the prior estimate of $650 million to $690 million.
Analyst Community Responds with Higher Targets
The strong quarterly results and raised guidance prompted several Wall Street firms to reassess their valuations for Acadia, resulting in a series of upward revisions to price targets:
- Stifel lifted its target to $24 from $18.
- Mizuho increased its target to $24, up from $23.
- Citizens JMP raised its target to $38 from $37 and reaffirmed its “Market Outperform” rating on the stock.
Upcoming Investor Events in the Spotlight
Market participants are now looking ahead to key events on the company’s calendar. Acadia is scheduled to present at three major investor conferences in September 2025, including the Morgan Stanley Global Healthcare Conference and the H.C. Wainwright Global Investment Conference. These events are anticipated as potential platforms for management to provide new strategic insights, particularly regarding its focus on neuro rare diseases.
Ad
Acadia Stock: Buy or Sell?! New Acadia Analysis from January 11 delivers the answer:
The latest Acadia figures speak for themselves: Urgent action needed for Acadia investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 11.
Acadia: Buy or sell? Read more here...
